WILMINGTON, N.C. (April 20, 2015) – Pharmaceutical Product Development, LLC (PPD) has opened a central laboratory in Shanghai, China, to deliver global scientific and technical laboratory expertise to meet growing client demand for these services in China. The new facility, which has been established in association with Shanghai Clinical Research Center (SCRC), is equipped with cutting-edge analytical equipment to provide high-quality data across a wide range of technologies and applications for all phases of pharmaceutical development.
The central lab service offering of PPD® Laboratories includes safety and general lab testing, specialized testing, biomarker testing, and custom assay development and testing services. This new operation provides the same services as PPD’s other central labs in Brussels, Belgium; Highland Heights, Kentucky; and Singapore. All of PPD’s central labs use identical testing platforms, calibrators and reagents for all laboratory assays. In addition, the same lot numbers of standards for calibration are used across all labs, ensuring identical results regardless of where testing is performed.
“Our global network of central labs is committed to bringing value across the product development continuum,” said Andrew Cunningham, Ph.D., vice president of global laboratory services at PPD. “We deliver world-class scientific expertise, innovative platforms, flexible service models and operational efficiencies to ensure successful execution across every step of the development process. The standardized, global platforms and Web-based database of our central labs ensure superior service, quality data, and exceptional speed and flexibility for our clients.”
The Shanghai laboratory leverages PPD’s 30 years of global laboratory expertise, broad therapeutic experience, and state-of-the-art facilities and instrumentation in delivering best-in-class laboratory services for its clients.
The new facility is accredited via SCRC’s medical license issued by China’s Ministry of Health, as well as the College of American Pathologists, NGSP and ISO 15189 certifications-all of which are crucial to conducting clinical trials in China successfully.
In addition to central labs, PPD Laboratories also includes: good manufacturing practices (GMP) labs in Athlone, Ireland, and Middleton, Wisconsin; bioanalytical labs in Middleton and Richmond, Virginia; and vaccine sciences labs in Richmond and Wayne, Pennsylvania. PPD also has strong clinical development expertise, which is supported by 20 facilities throughout the Asia Pacific region.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.